National speakers

IF 1.4 4区 医学 Q4 ONCOLOGY
{"title":"National speakers","authors":"","doi":"10.1111/ajco.14021","DOIUrl":null,"url":null,"abstract":"<p></p><p><b>Dr George Au-Yeung</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr George Au-Yeung is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interests in molecular biology of ovarian cancer as well as running novel biomarker driven clinical trials and translational research. He completed his PhD in Professor David Bowtell's laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist at Peter Mac, working across the Gynae-Oncology and Melanoma service, and is Co-Deputy Director of Medical Oncology. He is an active member of ANZGOG, and holds current and former positions with the Royal Australasian College of Physicians (RACP) and the Medical Oncology Group of Australia (MOGA).</p><p></p><p><b>Kira Bloomquist</b></p><p><i>Griffith University, UCSF, Copenhagen University Hospital</i></p><p>I am a physical therapist and research fellow, currently affiliated with the University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Denmark and Menzies Health Institute Queensland, Griffith University. My main areas of interest relate to “cancer survivorship” and draw on personal hands-on experiences with cancer survivors as a physical therapist since 1999, as well as experiences gained while undertaking various research roles (e.g., data collector, research assistant, and primary investigator) since 2003. My specific expertise relates to understanding the physical and psychosocial concerns faced following cancer, in particular lymphedema, and the role of exercise in cancer recovery.</p><p></p><p><b>A/Prof Anna Boltong</b></p><p><i>Cancer Australia</i></p><p>Associate Professor Anna Boltong is the Head of the Cancer Control Strategy Branch at Cancer Australia. A dietitian by training, Anna's background spans domestic and international leadership in clinical oncology, supportive care research, policy development, health inequalities, and education. At Cancer Australia, Anna oversees the development and implementation of the Australian Cancer Plan as well as the Optimal Care Systems and Indigenous Cancer Control portfolios.</p><p></p><p><b>A/Prof Angie Bone</b></p><p><i>Monash University</i></p><p>Angie is an Associate Professor of Practice in planetary health at the Monash Sustainable Development Institute, where she focuses on system transformation for health sector resilience and sustainability, behaviour change and planetary health. She is a senior public health physician and former Deputy Chief Health Officer in Victoria, with over 15 years of public health leadership and research experience on environmental influences on health and health equity. Angie works with a range of disciplines across the research/policy/practice interface, providing public health technical expertise combined with policy and implementation experience, to strengthen the evidence on the health impacts of climate change and the interventions to reduce risk, including tackling the wider, ‘upstream’ factors that influence the likelihood and severity of harm to health and wellbeing. Angie has co-authored over 40 peer-reviewed articles and book chapters, and has presented at numerous forums nationally and internationally on climate change, sustainability and health.</p><p></p><p><b>Prof Julia Brotherton</b></p><p><i>University of Melbourne</i></p><p>Prof Julia Brotherton is a public health physician, epidemiologist and Professor of Cancer Prevention Policy and Implementation at the Melbourne School of Population and Global Health, University of Melbourne. She is also a Professorial Fellow at the National Centre for Immunization Research and Surveillance. For over 15 years, Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination and cervical screening programs. She is co-chair of the CHIC global HPV Vaccine Council and is a CI on both the NHMRC Centre of Research Excellence (CRE) in Cervical Cancer Control (C4) and the NHMRC CRE in Targeted Approaches to Improve Cancer Services for Aboriginal and Torres Strait Islander Australians (TACTICS).</p><p></p><p><b>Prof Karen Canfell</b></p><p><i>Daffodil Centre, The University of Sydney</i></p><p>Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a flagship center of the University of Sydney and a joint venture with Cancer Council NSW, Australia. She is also Professor &amp; NHMRC Leadership Fellow, Faculty of Medicine and Health, The University of Sydney. Her research involves evaluation and translation of new strategies for cancer control, and she has led multiple impact and economic evaluations for government agencies in Australia and internationally. For example, her work underpins the transformation of the National Cervical Screening Program in Australia, which in 2017 moved to HPV DNA testing to replace Pap smears and the Daffodil Centre team have been actively engaged in the evaluation of lung cancer screening. She is active in global health and her team's work underpins the impact and investment case for the 2020 WHO strategic plan for cervical cancer elimination; in the period 2020–2021, her team has supported WHO in development of detailed clinical management guidelines for cervical screening in low-income countries. In 2020 she initiated, and co-leads with Dr. Freddie Bray from the International Agency for Research on Cancer (IARC), the International Partnership for Resilience in Cancer Systems (I-PaRCS) with key partners IARC, the International Cancer Screening Network, the Canadian Partnership Against Cancer, and the Daffodil Centre. I-PaRCS works to support decision-making across cancer control, during and emerging from the COVID-19 pandemic.</p><p></p><p><b>Dr Stefanie Carino</b></p><p><i>Climate and Health Alliance</i></p><p>Dr Stefanie Carino is a Sustainable Healthcare Program Manager at the Climate and Health Alliance where she coordinates Global Green and Healthy Hospitals in the Pacific region. She completed her PhD in environmentally sustainable foodservices and also works as a sustainable food systems dietitian at a public hospital.</p><p></p><p><b>Jordan Casey</b></p><p><i>Western Health</i></p><p>Jordan Casey is the Manager of Aboriginal Health, Policy &amp; Planning at Western Health. Jordan oversees the Wilim Berrbang (Aboriginal Health Unit) as well as being responsible for the implementation of the Aboriginal Health Cultural Safety Plan for Western Health. Jordan is passionate about bringing cultural safety into mainstream health services.</p><p></p><p><b>Dr Wanda Cui</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr Wanda Cui is a medical oncologist at the Peter MacCallum Cancer Centre and a PhD candidate at the University of Melbourne with a special interest in oncofertility and cancer in pregnancy. She has recently returned from a fellowship at the Royal Marsden Hospital. Her research focuses on improving our understanding of the impact of cancer therapies on fertility and ovarian function.</p><p></p><p><b>A/Prof Stephen David</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Associate Professor Steven David is a radiation oncologist at Icon Cancer Centre Mulgrave and PeterMac. A/Prof David graduated from the University of Western Australia and completed his specialist training at the Peter MacCallum Cancer Centre in Melbourne. Subsequently, he took up a position as a sub-specialist in breast and lung cancer. Steven has been the lead investigator in a number of investigator-initiated local, national, and multi-center clinical trials. His current areas of research include development and implementation of a Deep Inspiration Breath Hold Technique to reduce radiation to the heart for patients with left sided breast cancer and the use of high dose precision radiation (SABR) for the treatment of patients with oligometastatic disease.</p><p></p><p><b>Dr Rachel Delahunty</b></p><p><i>Mercy Hospital for Women, Peter MacCallum Cancer Centre, Geelong University Hospital</i></p><p>Dr Rachel Delahunty is a medical oncologist at The Mercy Hospital for Women, The Peter MacCallum Cancer Centre, and Geelong University Hospital and has a special interest in gynecological oncology and translational and clinical research. Rachel was recently awarded her PhD through the University of Melbourne and Peter MacCallum Cancer Centre titled “Reducing the morbidity and mortality of ovarian cancer through prevention which included leading the ovarian cancer prevention project ‘TRACEBACK’”.</p><p></p><p><b>Dr Abbey Diaz</b></p><p><i>University of Queensland</i></p><p>Dr Abbey Diaz is a Faculty of Medicine Research Fellow and Cancer Research Lead in the First Nations Cancer and Wellbeing Research Program at the University of Queensland. Dr Diaz is currently working with her team and collaborators to investigate cardiovascular risk, care, and experiences among Aboriginal and Torres Strait Islander people diagnosed with cancer. As part of this work Dr Diaz is working with an advisory panel of Aboriginal and Torres Strait Islander people affected by cancer, who identified a need for the co-design of culturally responsive cardio-oncology resources.</p><p></p><p><b>Dr Polly Dufton</b></p><p><i>University of Melbourne/Austin Health</i></p><p>Polly is a Registered Nurse at the Olivia Newton John Cancer, Research and Wellness Centre and has worked in a number of clinical and supportive care roles. She is currently undertaking her PhD at The University of Melbourne looking at emergency department presentations by cancer patients having ambulatory cancer treatment.</p><p></p><p><b>Ben Felmingham</b></p><p><i>Royal Children's Hospital</i></p><p>Mr Ben Felmingham is a pediatric pharmacist who completed his pharmacy training at the Royal Children's Hospital, Melbourne (RCH). He then went on to specialize in pediatric oncology, in which he is well versed with over 10 years of experience in all pediatric cancer streams including bone marrow transplantation. In 2021, under the Australian Cardio-oncology Registry (ACOR) umbrella of research work, Ben led the development of the first ever pediatric cardio-oncology guidelines. He has implemented and currently co-ordinates the multidisciplinary cardio-oncology clinic based at RCH. Ben is currently working as an academic pharmacist and senior research officer within the Murdoch Children's Research Institute (MCRI). Ben has a growing interest pediatric cardio-oncology as well as the pharmacogenomics field. His passion in these areas have led him to create and promote awareness of the growing importance of cardio-oncology and the importance of incorporating pharmacogenomics into practice. This in turn has led Ben to begin work on multiple research projects where he is expanding his expertise into looking at the effects of pharmacogenomic screening for potential gene–drug interactions, and thus providing and investigating therapeutic recommendations for actionable variants within the pediatric oncology population.</p><p></p><p><b>Prof Michael Friedlander</b></p><p><i>University of NSW, Prince of Wales Hospital, Royal Hospital for Women</i></p><p>Professor Michael Friedlander is a Conjoint Professor of Medicine at the University of NSW and a medical oncologist at the Prince of Wales Hospital and Royal Hospital for Women in Sydney Australia. His clinical and research interests have focused largely on the management of people with gynecological and breast cancers and improving outcomes through clinical trials and patient centered research. Over the course of his career which spans four decades, he has had a leading role in gynecological cancer clinical trials both nationally and internationally. He has held many leadership positions including inaugural chair of ANZGOG and President of the IGCS amongst many others. He has a longstanding interest in cancer genetics been closely involved since 2007 in both early and later phase trials of PARP inhibitors in ovarian and breast cancer which remains an area of major interest. He has received numerous awards in recognition of his contribution to gynecological oncology.</p><p></p><p><b>Prof Paul Glare</b></p><p><i>Northern Clinical School, University of Sydney</i></p><p>Professor Paul Glare is the Chair of Pain Medicine in the Northern Clinical School of the University of Sydney, based at Royal North Shore Hospital. He has various other leadership roles in pain medicine including with Sydney Medical School, the Kolling Institute, and the Australian &amp; NZ College of Anaesthetists. Prior to commencing his current appointment in 2016, he worked in palliative care in Australia and the USA, including as Chief of the Pain and Palliative Care Service at Memorial Sloan Kettering Cancer Center 2008–2016. Paul has two main research interests currently. One is chronic pain in cancer survivors, which is the topic of today's talk. The other is using digital technology to support health behavior change in patients wanting to taper off long term opioid therapy.</p><p></p><p><b>A/Prof Shom Goel</b></p><p><i>University of Melbourne and Peter MacCallum Cancer Centre</i></p><p>Associate Professor Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre. Having spent 10 years in Boston, where he completed his doctoral and postdoctoral research, A/Prof Goel returned to Australia in 2019. In addition to maintaining a clinical practice as an oncologist, he also leads a research group which positions itself at the intersection of cell cycle biology, epigenetics, and tumor immunology in breast cancer. They have developed several new transgenic mouse models of breast cancer, which have proven valuable for uncovering new mechanisms of drug activity and resistance, and their work has been published in high-impact journals including Nature, Cancer Cell, and Nature Cancer. He serves as either Global PI or Translational PI for four randomized clinical trials in breast cancer and was recently appointed Chair of the American Society of Clinical Oncology Education Committee. A/Prof Goel is also an awardee of a prestigious Snow Fellowship which will accelerate his laboratory's work from 2022 to 2030.</p><p></p><p><b>Victoria Gurvich</b></p><p><i>BCNA Consumer Representative</i></p><p>Victoria Gurvich was diagnosed with breast cancer at age 44. She underwent 18 months of active treatment, including neoadjuvant chemotherapy, surgeries, and radiation, and is still on medication. Victoria is a trained Consumer Representative (CR) for Breast Cancer Network Australia (BCNA), she is an occasional contributor to BCNA's publication The Beacon, and her areas of particular interest include cancer prevention, genetics, lymphedema, osteoporosis, and psycho-social impacts of cancer and its treatment.</p><p></p><p><b>A/Prof Barbara Hayes</b></p><p><i>Northern Health</i></p><p>Associate Professor Barbara Hayes is the Clinical Lead for Advance Care Planning at Northern Health in metropolitan Melbourne. She has a background in palliative medicine and a PhD in “Ethical CPR decision making”. Barbara has research and teaching interests in ethics and law related to end-of-life decision-making, informed consent, and shared decision making.</p><p></p><p><b>Dr Jolyn Hersch</b></p><p><i>The University of Sydney</i></p><p>Dr Jolyn Hersch is an Early Career Researcher at The University of Sydney, working at the interface between psychology and public health. She is a member of the Sydney Health Literacy Lab and the national Wiser Healthcare collaboration. Jolyn's research focuses on improving communication to support people to make better informed healthcare decisions consistent with their personal values. She is particularly interested in psychosocial aspects of screening and testing, and contexts where issues around potential overdiagnosis and overtreatment are relevant. Jolyn is currently supported by a Cancer Institute NSW fellowship to work on improving informed consent around genomic testing in oncology.</p><p></p><p><b>A/Prof Erin Howden</b></p><p><i>Baker Heart and Diabetes Institute</i></p><p>Associate Professor Erin Howden is the head of the Cardiometabolic Health and Exercise Physiology Lab and leads the Physical Activity Program at the Baker Heart and Diabetes Institute. In 2020, Erin was awarded a Heart Foundation Future Leader Fellowship to investigate the cardioprotective role of exercise in patients treated for cancer. Erin's program of research seeks to enhance the prevention and treatment of cardiometabolic disease in at risk cancer groups through developing innovative multidisciplinary approaches, with a particular focus on “exercise as medicine”. </p><p></p><p><b>Safeera Hussainy</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Safeera is Senior Pharmacy Research Manager at Peter MacCallum Cancer Centre, Adjunct Associate Professor at Monash University, and Honorary Principal Fellow at University of Melbourne. Recognized as the national pharmacy expert in emergency contraception, Safeera is Chief Investigator on SPHERE, an NHMRC Centre for Research Excellence in women's health, and on the MRFF ALLIANCE trial that aims to expand pharmacists’ scope of practice in contraceptive and abortion care service delivery. Safeera is also Chief Investigator on the MRFF PRECISION trial, leading the education strategy for the implementation of a pharmacogenomics program for pharmacists.</p><p></p><p><b>Dr Simon Hyde</b></p><p><i>Mercy Health</i></p><p>Dr Simon Hyde is Head of Gynaecological Oncology, Mercy Hospital for Women. He specializes in gynecological oncology, complex gynecologic surgery, colposcopy and preinvasive genital tract disease, and operative laparoscopy.</p><p></p><p><b>Viv Interrigi</b></p><p><i>Consumer Representative</i></p><p>Viv Interrigi is a mother, a partner, a daughter, a sister, and a breast cancer survivor. She was diagnosed in 2018 and went through a lumpectomy, chemotherapy, radiotherapy, infusions and has been on medications for the past 5 years. As a cancer survivor, she has had to find different ways of leaning on supports as cancer is a chronic disease that never ever completely leaves her world. She is continually using her cancer experience to volunteer as a consumer advisor – to increase the voice of the patient in decision making and to raise awareness of the importance of cancer research – to hopefully one day, have zero deaths from cancer.</p><p></p><p><b>Prof Michael Jefford</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Professor Michael Jefford is a Consultant Medical Oncologist and Director of the Australian Cancer Survivorship Centre at Peter MacCallum Cancer Centre and is a Professorial Fellow at the University of Melbourne. His major clinical focus is on the management of people with gastrointestinal cancers; most of his research has a cancer survivorship focus. He is widely published (&gt;220 publications at June 2023) and has presented at numerous international meetings.</p><p></p><p><b>A/Prof Louise Koelmeyer</b></p><p><i>Macquarie University</i></p><p>Associate Professor Louise Koelmeyer is the Head, Department of Health Sciences and Director of the Australian Lymphoedema Education, Research and Treatment (ALERT) program within the Faculty of Medicine, Health and Human Sciences at Macquarie University. Louise is a lymphedema therapist (occupational therapist), educator, and researcher with over 30 years of experience in both public and private settings specializing in breast cancer rehabilitation and lymphedema management. Louise is involved in strategically managing and developing the education, research, and treatment arms of the innovative and internationally recognized “Centre of Excellence” multidisciplinary program.</p><p></p><p><b>Prof Bogda Koczwara</b></p><p><i>Flinders Medical Centre</i></p><p>Professor Koczwara is a senior staff specialist in medical oncology at the Flinders Medical Centre in Adelaide, Australia and she leads the Survivorship Research Program at the Flinders University Health and Medical Research Institute. Professor Koczwara established one of the first cancer survivorship program in Australia and has contributed to key advancers in the field including survivorship epidemiology, self-management support, and the use of patient reported outcomes in cancer. She chairs the Multinational Association of Supportive Care in Cancer Psychosocial Study Group, the International Cardiooncology Society Survivorship Working Group and is the convenor of the Global Partnership on Self-management in Cancer. She co-chairs the joint Clinical Oncology Society of Australia and Cardiac Society of Australia and New Zealand Cardio-Oncology Working Group and leads a national Working Group on implementation of patient reported outcomes in cancer. She is the initiator of the Australia Asia Pacific Clinical Oncology Research Development, a collaborative of international cancer organizations aimed at improving cancer research capacity in Australia and Asia Pacific. She has been recognized as a Member of the Order of Australia for her services to oncology.</p><p></p><p><b>Dr Michael Krasovitsky</b></p><p><i>St Vincent's Hospital</i></p><p>Dr Michael Krasovitsky is a medical oncologist at St Vincent's Hospital, Sydney. He specialises in geriatric oncology, and leads both the geriatric oncology clinic and multidisciplinary team at St Vincent's Hospital. His other clinical interests include supportive care &amp; toxicity assessment, gastrointestinal cancers, and thoracic cancers. He is the chair of the Geriatric Oncology Emerging Experts and Researchers group, a multidisciplinary collective of clinicians dedicated to geriatric oncology, and is also a proud member of the Geriatric Oncology COSA executive. Dr Krasovitsky is passionate about improving outcomes, both malignancy and quality of life related, for older individuals with cancer, and has a particular interest in tackling ageism in cancer care and health care generally.</p><p></p><p><b>Prof Mei Krishnasamy</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Professor Mei Krishnasamy PhD, FAAN, is Director of the Academic Nursing Unit at the Peter MacCallum Cancer Centre and honorary Chair in Cancer Nursing at the University of Melbourne. She is Research and Education Lead for Nursing for the VCCC Alliance, and co-lead of the Victorian Regional Research Teaching Hub program as part of the Victorian ReVitalise initiative. Mei is past President of the Clinical Oncology Society of Australia and the Cancer Nurses of Australia and is Fellow of the American Academy of Nursing. Her research focuses on cancer supportive care, health equity and experiences of care for people with poor prognosis cancers, and the contribution of nurses to patient and system level outcomes.</p><p></p><p><b>Dr Heather Lane</b></p><p><i>Sir Charles Gairdner Hospital</i></p><p>Dr Heather Lane, MBChB, FRACP, PhD is a Consultant Geriatrician and the Director of Physician Education at Sir Charles Gairdner Hospital in Perth, where she has established a Geriatric Oncology Clinic. She is the Australian National representative for the International Society of Geriatric Oncology (SIOG), and a member of the SIOG Geriatricians Group. She is also a member of the COSA Geriatric Oncology Special Interest Group Executive.</p><p></p><p><b>Dr Joshua Lin</b></p><p><i>Barwon Health</i></p><p>Dr Joshus Lin is a breast and melanoma surgeon from Geelong, Australia, with a career journey that has taken him across every Australian state. He completed his fellowship at Sir Charles Gairdner Hospital in Perth and the Royal North Shore Hospital and Melanoma Institute Australia in Sydney. However, it was his tenure in Far North Queensland and Tasmania that shaped his current interest in regional living and work. Josh particularly enjoys the oncoplastic aspects of breast surgery and appreciates being able to extend this regionally.</p><p></p><p><b>Prof Geoff Lindeman</b></p><p><i>Peter MacCallum Cancer Centre and Royal Melbourne Hospital</i></p><p>Professor Geoff Lindeman, a clinician-scientist, is Joint Head of the Cancer Biology and Stem Cells Division at the Walter and Eliza Hall Institute. He is also a medical oncologist at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital and holds an honorary appointment as Professorial Fellow in the Department of Medicine, University of Melbourne. He established the RMH Familial Cancer Centre and was inaugural Director of the Parkville Familial Cancer Centre. His group is interested in the molecular and cellular regulators of normal mammary gland development and changes that lead to hereditary and sporadic breast cancer. The discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers has led to the international breast cancer prevention trial, BRCA-P.</p><p></p><p><b>A/Prof Cheng Hean Lo</b></p><p><i>Western Health</i></p><p>Associate Professor Cheng Hean Lo is a specialist plastic &amp; reconstructive surgeon. He is the current Head of Department of Plastic &amp; Reconstructive Surgery at Western Health, and is a senior medical staff at the Victorian Adult Burns Service (The Alfred). He has published at least 45 articles in peer-reviewed journals of international standing and he has been involved with successful grant and funding applications totaling in excess of $3 million. His areas of particular interest include skin tissue engineering in the setting of burn injuries, and gender affirming surgery.</p><p></p><p><b>Prof Sherene Loi</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Professor Loi is a Medical Oncologist specialized in breast cancer treatment as well as a clinician scientist (group leader) with expertise in genomics, immunology and drug development at the Peter MacCallum Cancer Centre, Melbourne, Australia. She is recognized internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology field as well as leading international clinical trials in breast cancer immunotherapy. To date, she has published over 300 peer-reviewed research articles with a lifetime H-index of &gt;100. Her recent work has been highly influential: she is ranked in the top 1% of highly cited researchers globally by the Web of Science. She co-chairs the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland, one of the largest global academic breast cancer trial cooperative groups. She is a current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and in 2021 received one the Prime Ministers’ Awards for Science.</p><p></p><p><b>Dr Stephen Luen</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr Stephen Luen is an early career Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre specialising in breast cancer, sarcoma, early drug development, and precision oncology. In 2021, he completed a PhD supervised by Professor Sherene Loi investigating genomic and immune biomarkers in early-stage breast cancers, and continues to work closely with the laboratory. His current research interests include the study of genomic and immune biomarkers in high-risk and treatment-refractory breast cancers, the development of novel clinical trial approaches for high-risk breast cancers, and the early phase development of new therapeutic compounds.</p><p></p><p><b>Jodie Lydeker</b></p><p><i>BCNA Consumer Representative</i></p><p>Jodie Lydeker is a lawyer by training and has spent over 20 years in the public sector leading national and state-wide social policy reforms in the areas of criminal justice, education, mental health and anti-corruption. But a diagnosis of invasive breast cancer 5 years ago at the age of 40 carved out a new pathway into public health. After being part of the Victorian Government's COVID-19 response and a brief stint in Canberra leading national mental health reforms for the Australian Department of Health, Jodie is now the managing director of her own policy and project management company. Outside of work, Jodie is a proud consumer representative with BCNA, Cancer Council Victoria, Genesis Care and the Psycho-oncology Co-operative Research Group (PoCoG) at the University of Sydney. In addition to qualifications in law and business, she has studied psychosocial oncology and service navigation to help advocate for improved availability of integrative care models that prioritise emotional health and wellbeing for people impacted by cancer. She is currently writing her book called ‘<i>Strong Enough to Break</i>’ that reflects on her experiences of both cancer and mental illness to encourage people to give themselves permission to pause.</p><p></p><p><b>A/Prof Brigid Lynch</b></p><p><i>Cancer Council Victoria, University of Melbourne</i></p><p>Associate Professor Brigid Lynch is a cancer epidemiologist whose research focuses on how physical activity is associated with cancer risk, biological mechanisms underlying risk, and health outcomes for cancer survivors. Her research interests include applying causal inference methods to help advance the field of physical activity epidemiology. Brigid is a Principal Investigator of the Australian Breakthrough Cancer Study, an ongoing cohort study of over 50,000 Australians investigating the role that genes, lifestyle, and environment play in the development of cancer and other diseases.</p><p></p><p><b>Prof Bruce Mann</b></p><p><i>Victorian Comprehensive Cancer Centre</i></p><p>Professor Bruce Mann is Director of the Breast Tumour Stream of the Victorian Comprehensive Cancer Centre. He is also Director of Research at Breast Cancer Trials – Australia and New Zealand's cooperative breast cancer clinical trials organization. His interests relate to systems for optimal breast cancer care and research to improve early diagnosis and tailor the extent of breast cancer treatment to the individual patient.</p><p></p><p><b>A/Prof Forbes McGain</b></p><p><i>Western Health, University of Melbourne</i></p><p>Associate Professor Forbes McGain is an anesthetist and intensive care physician at Western Health, Melbourne, Australia, and Associate Dean, Sustainable Healthcare, University of Melbourne. Forbes enjoys research, teaching, and education at the hospital, university, and beyond. During COVID-19 Forbes received the Clunies Ross Award for co-creating the patented McMonty personal isolation hood to protect healthcare workers. Collaboratively, Forbes is now embarking upon further innovative solutions to make healthcare more sustainable. He is a co-lead on the Lancet Commission for Sustainable Healthcare.</p><p></p><p><b>Dr Alexandra Murphy</b></p><p><i>Victorian Heart Hospital and Austin Health</i></p><p>Dr Alexandra Murphy graduated from the University of Melbourne with a Bachelor of Medicine/Bachelor of Surgery and Bachelor of Medical Science. She entered the Cardiology Advanced Training program at the Austin Hospital following which she became a Fellow of the Royal Australasian College of Physicians (FRACP). Alex has completed advanced fellowships in cardiac imaging, imaging for structural intervention, and cardio-oncology. Dr Murphy's PhD focuses on the optimization of cardiovascular outcomes in cancer patients and was supported by scholarships from the NHMRC, National Heart Foundation and Cardiac Society of Australia and New Zealand. The centerpiece of her research was the SMART-BREAST randomized controlled trial which demonstrated the efficacy of her patented smartphone application BreastMate in the exercise promotion and cardiovascular risk reduction of early stage breast cancer patients. From this she was awarded a Fulbright Scholarship to continue her research at Mount Sinai Hospital in New York City. Dr Murphy is now a cardio-oncologist at the newly established Victorian Heart Hospital and Austin Health.</p><p></p><p><b>Naveena Nekkalapudi</b></p><p><i>BCNA Consumer Representative</i></p><p>Following her diagnosis of triple negative breast cancer and the subsequent treatment, Naveena decided to re-evaluate her life and focus on matters that are important to her. She describes it as changing from being career ambitious to being life ambitious, that is, wanting to utilize her varied skills and knowledge in assisting others to achieve better health outcomes. In her previous (corporate) life, she was a senior professional with extensive strategy, research, M&amp;A, and management skills across a range of industries – dairy, trustee, funds management, and private health insurance. Naveena has an M. B. A. from Melbourne Business School and is a consumer representative of BCNA, Cancer Council Victoria, Breast Cancer Trials, VCCC, and Walter and Eliza Hall Institute of Medical Research to name a few.</p><p></p><p><b>Kerry Patford</b></p><p><i>McGrath Foundation</i></p><p>With 20 years of Breast Care Nurse experience, Kerry has a special interest in accessible and equitable care in regional and rural areas. A McGrath Breast Care Nurse since 2009, more recently Kerry has worked with the McGrath Foundation in developing the Model of Care, with the original version released in 2019, and the reviewed Model of Care for Early Breast Cancer released in 2023. Sharing her time now within the clinical space of her McGrath BCN role, Kerry works within a team of Clinical Leaders at the McGrath Foundation.</p><p></p><p><b>Dr Elizabeth Pearson</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr Elizabeth Pearson is an occupational therapist and allied health researcher working at the Peter MacCallum Cancer Centre in Melbourne, Australia. Her main goal in both roles has been to help people with cancer live their lives as well as possible, for as long as possible.</p><p>Elizabeth's recent research has explored the feasibility of implementing evidence-based guidelines and stepped-care cognitive behavior therapy to address the common problem of cancer-related fatigue.</p><p></p><p><b>A/Prof Michelle Peate</b></p><p><i>University of Melbourne</i></p><p>Associate Professor Michelle Peate is the Program Leader for the Psychosocial Health and Wellbeing Research (emPoWeR) Unit, University of Melbourne. She was a 2011 NSW Young Tall Poppy from the Australian Institute for Policy in Science and 2017 International Psycho-Oncology Society New Investigator Award winner. She is President of the Australian Society of Obstetrics and Gynaecology and sits on several clinical guideline committees and advisory panels, including the COSA fertility preservation guideline committee. Her main goal is to develop evidence-based interventions that improve patient experiences at the intersection of cancer, reproductive health, and psychology.</p><p></p><p><b>Dr Melanie Plinsinga</b></p><p><i>Menzies Health Institute</i></p><p>Dr Melanie Plinsinga is an early career researcher in the field of symptom research, with particular interest in exercise management and rehabilitation. Her current work uses her expertise to address unanswered questions in cancer-related pain and lymphedema to improve lives through the prevention and better management of survivorship symptoms.</p><p></p><p><b>Hildegard Reul-Hirche</b></p><p><i>Royal Brisbane and Women's Hospital</i></p><p>Ms Reul-Hirche has been an honorary Research Fellow at the Physiotherapy Department at the Royal Brisbane and Women's Hospital (RBWH) since April 2019. She is a physiotherapist with over 30 years of clinical experience treating lymphedema. Ms Reul-Hirche is the founder, curriculum leader, and co-facilitator of Lymphoedema Training Modules accredited by the Australasian Lymphology Association (ALA) and presented at RBWH. She is an accredited lymphedema therapist with the ALA and a titled lymphedema physiotherapist under the Australian Physiotherapy Association. At present she is completing her MPhil at Griffith University (Nathan).</p><p></p><p><b>Gail Rowan</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Gail's main area of practice and interest includes the treatment of hematological malignancies, minimization of anti-cancer therapy related adverse effects and education on the safe use of anti-cancer therapies especially oral therapies. Gail is past chair and a current committee member of the Cancer Pharmacists Group (CPG) of COSA, and a member of the Leadership Committee of the SHPA Oncology &amp; Haematology Specialty Practice Group, and is qualified as a Board Certified Oncology Pharmacist (BCOP) through the Board of Pharmaceutical Specialities in the United States.</p><p></p><p><b>Prof Christobel Saunders</b></p><p><i>University of Melbourne, Royal Melbourne Hospital, Peter MacCallum Cancer Institute</i></p><p>Professor Christobel Saunders AO, MB BS, FRCS, FRACS, FAAHMS is the James Stewart Chair of Surgery, the Head of the Department of Surgery at the University of Melbourne (Royal Melbourne Hospital precinct), Director of Medical Research at Melbourne Medical School, and consultant surgeon in the Department of General Surgery at Royal Melbourne Hospital and the Peter MacCallum Cancer Institute. Christobel is internationally recognized as one of Australia's most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research, including clinical trials of new treatments, and psychosocial, translational, and health services research. In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honors including the Order of Australia 2018, the Uccio Querci della Rovere Award (2018), WA Women's Hall of Fame Inductee (2018), WA Scientist of the Year (2017), Cancer Council WA Career Achievement Award (2021) and was elected to the Australian Academy of Health and Medical Science in 2016. She has performed research for &gt;30 years evaluating the efficacy and utility of therapy for early breast cancer. In the past 5 years, Christobel has published over 200 peer-reviewed journal articles. She sits on the boards of several health and research organizations including as Vice-President for All.Can International and on the boards of All.Can Australia, Breast Cancer Trials, the Australian Centre for Value-Based Health Care and PathWest. Christobel is closely involved in strategic planning and management of health and cancer services in Australia including being a member of the Medicare Review Advisory Committee, panel member of the Medical Services Advisory Committee, past President of the Breast Surgical Society of ANZ, and past Advisory Council member of Cancer Australia. She was the Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine.</p><p></p><p><b>Dr Peter Savas</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr Peter Savas is a medical oncologist, clinical trial investigator, and clinician scientist specializing in breast cancer. With broad interests in breast cancer genomics, the immune microenvironment, and applications of artificial intelligence in histology, Dr Savas’ current work is focused on enabling precision oncology approaches in advanced and early stage breast cancer, and the use of single cell methods to interrogate the immune response to invasive breast cancer.</p><p></p><p><b>A/Prof Camille Short</b></p><p><i>University of Melbourne</i></p><p>Associate Professor Camille Short is behavioral scientist and Victoria Cancer Agency Mid-Career Fellow. She works at the University of Melbourne within the Melbourne Centre for Behaviour Change and the CanRex Exercise and Recovery Research Group. Camille has experience and training in health psychology, digital, and public health. She leads a program of work focused on the use of technology for improving access to high quality, personalized, and multidisciplinary exercise support for cancer patients. As a behavioral scientist, she is passionate about ensuring exercise programs support people to make lifestyle changes by addressing the psychological, physical, and social factors that impact on exercise and access to exercise services. Camille's research has influenced policy and practice within Australian health services and is widely cited internationally.</p><p></p><p><b>Dr Olivia Smibert</b></p><p><i>Peter Mac Callum Cancer Center, University of Melbourne</i></p><p>Dr Smibert is an infectious diseases clinician at Austin Health and PhD student at the Peter Mac Callum Cancer Center and University of Melbourne. In 2019 she completed a fellowship at Massachusetts General Hospital, Harvard University in transplant infectious diseases.</p><p>She has earned a number of awards including the 2019 NHMRC Gustav Nossal Postgraduate Scholarship Award, an International investigator Award from the Infectious Diseases Society of America, an American Society of Transplant Fellows Award, and the RACP Richard Kemp Memorial Fellowship. She has contributed to over 49 peer-reviewed publications and is undertaking her PhD at the Peter MacCallum Cancer Centre through the Department of Oncology. Her PhD project aims to define the role of the microbiome in determining infectious and immunological outcomes in immune compromised specialty patient populations and how this could lead to novel therapeutics and diagnostics.</p><p></p><p><b>Dr David Speakman</b></p><p><i>Peter MacCallum Cancer Centre</i></p><p>Dr David Speakman is a Surgeon specializing in Breast Disease and Melanoma. He has over 20 years sub-specialist experience in these areas. Dr Speakman is particularly interested in the minimally invasive treatment of breast cancer involving breast conservation, oncoplastic techniques, sentinel node biopsy, and neo-adjuvant therapies. He was trained in breast reconstructive techniques as a Fellow and also works closely with dedicated Breast Plastic and Reconstructive Surgeons. He is also widely experienced in benign Breast Disease. He has had a long involvement with the breast screening program through assessment clinics as well as on the Scientific Advisory Committee of BreastScreen Victoria. Dr Speakman is active in clinical trial programs, in particular the large Z11 Trial in breast cancer and the MSLT II in melanoma. These are both international trials. He has taught medical students from both Melbourne and Monash Universities for the past 20 years. Communication in cancer care is critical. Dr Speakman has taught the “Breaking Bad News” communication skills course for clinicians at The Royal College of Surgeons for the past 10 years. Dr Speakman is the Chief Medical Officer and Executive Director Medical Services at the Peter MacCallum Cancer Centre and is a Senior Surgeon in both the Breast and Skin and Melanoma Units there. Dr Speakman believes that a strong connection between the patient and their entire treating team is vital in getting the best outcomes for patients with cancer.</p><p></p><p><b>A/Prof Kate Stern</b></p><p><i>Royal Women's Hospital</i></p><p>Associate Professor Kate Stern is Associate Professor of Obstetrics and Gynaecology at the University of Melbourne, Royal Women's Hospital. Kate is the Head of Reproductive Services at the Royal Women's Hospital, Melbourne and Clinical Director and Head of Clinical Research at Melbourne IVF. She co-chaired the COSA Fertility Preservation Guidance Committee. Kate is a fertility specialist, gynecologist, and reproductive endocrinologist and her special interest is in medical fertility preservation. She received the award of the Order of Australia in 2022.</p><p></p><p><b>Dr Wendy Vanselow</b></p><p><i>Royal Women's Hospital</i></p><p>Dr Wendy Vanselow is Head of Psychosexual Medicine at RWH. She has a background in General Practice and a PhD in psychiatry. She studied sexual medicine at Oxford University and became an inaugural Fellow of the European Committee for Sexual Medicine in 2012. At RWH she also consults in the Menopause after Cancer clinic.</p><p></p><p><b>A/Prof Lisa Whop</b></p><p><i>The Australian National University</i></p><p>Associate Professor Lisa Whop is a Gumulgal woman from the Wagadagam tribe of Mabuiag Island in the Torres Strait and is Australia's leading authority on cervical cancer control in Aboriginal and Torres Strait Islander women. Lisa is an Indigenist epidemiologist with experience in implementation health research to develop, inform, and change public health policy, guidelines, and practice. She holds a National Health and Medical Research Council Investigator Grant and is the lead of the cervical cancer elimination team in the National Centre for Aboriginal and Torres Strait Islander Wellbeing Research at the Australian National University. She is incoming Chair of the Cancer Australia Aboriginal and Torres Strait Islander Leadership Committee on Cancer Control.</p><p></p><p><b>Dr Joshua Wiley</b></p><p><i>Monash University</i></p><p>Dr Joshua Wiley is a behavioral medicine researcher working at Monash University and the Peter MacCallum Cancer Centre with a focus on understanding and improving sleep and mental health in people after cancer. His research has resulted in &gt;100 publications and &gt;$10 million in grant funding from both national and international agencies. His research has two main tracks: one focused on foundational knowledge gain such as understanding functions, trajectories, and correlates of sleep and mental health and the second focused on designing and evaluating brief, scalable interventions to improve sleep and mental health, often using digital and telehealth methods in randomized clinical trials.</p><p></p><p><b>Dr Aaron Wong</b></p><p><i>Peter McCallum Cancer Centre, The Royal Melbourne Hospital</i></p><p>Dr Aaron K Wong is a dual trained Palliative Care Physician and Medical Oncologist and Early Career Researcher. Aaron established the Palliative Care Clinical Trials Unit at Olivia Newton John Cancer and Wellness Centre (2018) and is currently Clinical Trials Lead at the Peter MacCallum Cancer Centre, and The Royal Melbourne Hospital. Aaron has been Chief Investigator on several palliative care clinical trials. He is completing a PhD supported by an NHMRC Postgraduate Scholarship focusing on investigating biomarkers using pharmacogenomics, for optimal selection of opioids for optimal pain control.</p><p></p><p><b>Dr Felicity Wright</b></p><p><i>Department of Health</i></p><p>Dr Felicity Wright is the Director of Pharmacy at Sydney Children's Hospital, Randwick and a Net Zero Clinical Lead for the Sydney Children's Hospital Network (SCHN). Felicity is a paediatric oncology and cellular therapy pharmacist by background, a Board-Certified Oncology Pharmacist (USA) with a PhD in pharmacogenetics and a Master of Public Health in health policy. Her recent health system research in decarbonisation adds carbon metrics to quality improvement and valued based care initiatives delivering measurable carbon reduction in clinical care, waste management and pharmaceutical procurement.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14021","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Dr George Au-Yeung

Peter MacCallum Cancer Centre

Dr George Au-Yeung is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interests in molecular biology of ovarian cancer as well as running novel biomarker driven clinical trials and translational research. He completed his PhD in Professor David Bowtell's laboratory, investigating novel therapeutic strategies for Cyclin E1 amplified high grade serous ovarian cancer, a subset of ovarian cancers that behave aggressively and lack treatment options. He is now a full-time medical oncologist at Peter Mac, working across the Gynae-Oncology and Melanoma service, and is Co-Deputy Director of Medical Oncology. He is an active member of ANZGOG, and holds current and former positions with the Royal Australasian College of Physicians (RACP) and the Medical Oncology Group of Australia (MOGA).

Kira Bloomquist

Griffith University, UCSF, Copenhagen University Hospital

I am a physical therapist and research fellow, currently affiliated with the University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Denmark and Menzies Health Institute Queensland, Griffith University. My main areas of interest relate to “cancer survivorship” and draw on personal hands-on experiences with cancer survivors as a physical therapist since 1999, as well as experiences gained while undertaking various research roles (e.g., data collector, research assistant, and primary investigator) since 2003. My specific expertise relates to understanding the physical and psychosocial concerns faced following cancer, in particular lymphedema, and the role of exercise in cancer recovery.

A/Prof Anna Boltong

Cancer Australia

Associate Professor Anna Boltong is the Head of the Cancer Control Strategy Branch at Cancer Australia. A dietitian by training, Anna's background spans domestic and international leadership in clinical oncology, supportive care research, policy development, health inequalities, and education. At Cancer Australia, Anna oversees the development and implementation of the Australian Cancer Plan as well as the Optimal Care Systems and Indigenous Cancer Control portfolios.

A/Prof Angie Bone

Monash University

Angie is an Associate Professor of Practice in planetary health at the Monash Sustainable Development Institute, where she focuses on system transformation for health sector resilience and sustainability, behaviour change and planetary health. She is a senior public health physician and former Deputy Chief Health Officer in Victoria, with over 15 years of public health leadership and research experience on environmental influences on health and health equity. Angie works with a range of disciplines across the research/policy/practice interface, providing public health technical expertise combined with policy and implementation experience, to strengthen the evidence on the health impacts of climate change and the interventions to reduce risk, including tackling the wider, ‘upstream’ factors that influence the likelihood and severity of harm to health and wellbeing. Angie has co-authored over 40 peer-reviewed articles and book chapters, and has presented at numerous forums nationally and internationally on climate change, sustainability and health.

Prof Julia Brotherton

University of Melbourne

Prof Julia Brotherton is a public health physician, epidemiologist and Professor of Cancer Prevention Policy and Implementation at the Melbourne School of Population and Global Health, University of Melbourne. She is also a Professorial Fellow at the National Centre for Immunization Research and Surveillance. For over 15 years, Julia has been involved in research and policy development informing the implementation and evaluation of HPV vaccination and cervical screening programs. She is co-chair of the CHIC global HPV Vaccine Council and is a CI on both the NHMRC Centre of Research Excellence (CRE) in Cervical Cancer Control (C4) and the NHMRC CRE in Targeted Approaches to Improve Cancer Services for Aboriginal and Torres Strait Islander Australians (TACTICS).

Prof Karen Canfell

Daffodil Centre, The University of Sydney

Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a flagship center of the University of Sydney and a joint venture with Cancer Council NSW, Australia. She is also Professor & NHMRC Leadership Fellow, Faculty of Medicine and Health, The University of Sydney. Her research involves evaluation and translation of new strategies for cancer control, and she has led multiple impact and economic evaluations for government agencies in Australia and internationally. For example, her work underpins the transformation of the National Cervical Screening Program in Australia, which in 2017 moved to HPV DNA testing to replace Pap smears and the Daffodil Centre team have been actively engaged in the evaluation of lung cancer screening. She is active in global health and her team's work underpins the impact and investment case for the 2020 WHO strategic plan for cervical cancer elimination; in the period 2020–2021, her team has supported WHO in development of detailed clinical management guidelines for cervical screening in low-income countries. In 2020 she initiated, and co-leads with Dr. Freddie Bray from the International Agency for Research on Cancer (IARC), the International Partnership for Resilience in Cancer Systems (I-PaRCS) with key partners IARC, the International Cancer Screening Network, the Canadian Partnership Against Cancer, and the Daffodil Centre. I-PaRCS works to support decision-making across cancer control, during and emerging from the COVID-19 pandemic.

Dr Stefanie Carino

Climate and Health Alliance

Dr Stefanie Carino is a Sustainable Healthcare Program Manager at the Climate and Health Alliance where she coordinates Global Green and Healthy Hospitals in the Pacific region. She completed her PhD in environmentally sustainable foodservices and also works as a sustainable food systems dietitian at a public hospital.

Jordan Casey

Western Health

Jordan Casey is the Manager of Aboriginal Health, Policy & Planning at Western Health. Jordan oversees the Wilim Berrbang (Aboriginal Health Unit) as well as being responsible for the implementation of the Aboriginal Health Cultural Safety Plan for Western Health. Jordan is passionate about bringing cultural safety into mainstream health services.

Dr Wanda Cui

Peter MacCallum Cancer Centre

Dr Wanda Cui is a medical oncologist at the Peter MacCallum Cancer Centre and a PhD candidate at the University of Melbourne with a special interest in oncofertility and cancer in pregnancy. She has recently returned from a fellowship at the Royal Marsden Hospital. Her research focuses on improving our understanding of the impact of cancer therapies on fertility and ovarian function.

A/Prof Stephen David

Peter MacCallum Cancer Centre

Associate Professor Steven David is a radiation oncologist at Icon Cancer Centre Mulgrave and PeterMac. A/Prof David graduated from the University of Western Australia and completed his specialist training at the Peter MacCallum Cancer Centre in Melbourne. Subsequently, he took up a position as a sub-specialist in breast and lung cancer. Steven has been the lead investigator in a number of investigator-initiated local, national, and multi-center clinical trials. His current areas of research include development and implementation of a Deep Inspiration Breath Hold Technique to reduce radiation to the heart for patients with left sided breast cancer and the use of high dose precision radiation (SABR) for the treatment of patients with oligometastatic disease.

Dr Rachel Delahunty

Mercy Hospital for Women, Peter MacCallum Cancer Centre, Geelong University Hospital

Dr Rachel Delahunty is a medical oncologist at The Mercy Hospital for Women, The Peter MacCallum Cancer Centre, and Geelong University Hospital and has a special interest in gynecological oncology and translational and clinical research. Rachel was recently awarded her PhD through the University of Melbourne and Peter MacCallum Cancer Centre titled “Reducing the morbidity and mortality of ovarian cancer through prevention which included leading the ovarian cancer prevention project ‘TRACEBACK’”.

Dr Abbey Diaz

University of Queensland

Dr Abbey Diaz is a Faculty of Medicine Research Fellow and Cancer Research Lead in the First Nations Cancer and Wellbeing Research Program at the University of Queensland. Dr Diaz is currently working with her team and collaborators to investigate cardiovascular risk, care, and experiences among Aboriginal and Torres Strait Islander people diagnosed with cancer. As part of this work Dr Diaz is working with an advisory panel of Aboriginal and Torres Strait Islander people affected by cancer, who identified a need for the co-design of culturally responsive cardio-oncology resources.

Dr Polly Dufton

University of Melbourne/Austin Health

Polly is a Registered Nurse at the Olivia Newton John Cancer, Research and Wellness Centre and has worked in a number of clinical and supportive care roles. She is currently undertaking her PhD at The University of Melbourne looking at emergency department presentations by cancer patients having ambulatory cancer treatment.

Ben Felmingham

Royal Children's Hospital

Mr Ben Felmingham is a pediatric pharmacist who completed his pharmacy training at the Royal Children's Hospital, Melbourne (RCH). He then went on to specialize in pediatric oncology, in which he is well versed with over 10 years of experience in all pediatric cancer streams including bone marrow transplantation. In 2021, under the Australian Cardio-oncology Registry (ACOR) umbrella of research work, Ben led the development of the first ever pediatric cardio-oncology guidelines. He has implemented and currently co-ordinates the multidisciplinary cardio-oncology clinic based at RCH. Ben is currently working as an academic pharmacist and senior research officer within the Murdoch Children's Research Institute (MCRI). Ben has a growing interest pediatric cardio-oncology as well as the pharmacogenomics field. His passion in these areas have led him to create and promote awareness of the growing importance of cardio-oncology and the importance of incorporating pharmacogenomics into practice. This in turn has led Ben to begin work on multiple research projects where he is expanding his expertise into looking at the effects of pharmacogenomic screening for potential gene–drug interactions, and thus providing and investigating therapeutic recommendations for actionable variants within the pediatric oncology population.

Prof Michael Friedlander

University of NSW, Prince of Wales Hospital, Royal Hospital for Women

Professor Michael Friedlander is a Conjoint Professor of Medicine at the University of NSW and a medical oncologist at the Prince of Wales Hospital and Royal Hospital for Women in Sydney Australia. His clinical and research interests have focused largely on the management of people with gynecological and breast cancers and improving outcomes through clinical trials and patient centered research. Over the course of his career which spans four decades, he has had a leading role in gynecological cancer clinical trials both nationally and internationally. He has held many leadership positions including inaugural chair of ANZGOG and President of the IGCS amongst many others. He has a longstanding interest in cancer genetics been closely involved since 2007 in both early and later phase trials of PARP inhibitors in ovarian and breast cancer which remains an area of major interest. He has received numerous awards in recognition of his contribution to gynecological oncology.

Prof Paul Glare

Northern Clinical School, University of Sydney

Professor Paul Glare is the Chair of Pain Medicine in the Northern Clinical School of the University of Sydney, based at Royal North Shore Hospital. He has various other leadership roles in pain medicine including with Sydney Medical School, the Kolling Institute, and the Australian & NZ College of Anaesthetists. Prior to commencing his current appointment in 2016, he worked in palliative care in Australia and the USA, including as Chief of the Pain and Palliative Care Service at Memorial Sloan Kettering Cancer Center 2008–2016. Paul has two main research interests currently. One is chronic pain in cancer survivors, which is the topic of today's talk. The other is using digital technology to support health behavior change in patients wanting to taper off long term opioid therapy.

A/Prof Shom Goel

University of Melbourne and Peter MacCallum Cancer Centre

Associate Professor Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre. Having spent 10 years in Boston, where he completed his doctoral and postdoctoral research, A/Prof Goel returned to Australia in 2019. In addition to maintaining a clinical practice as an oncologist, he also leads a research group which positions itself at the intersection of cell cycle biology, epigenetics, and tumor immunology in breast cancer. They have developed several new transgenic mouse models of breast cancer, which have proven valuable for uncovering new mechanisms of drug activity and resistance, and their work has been published in high-impact journals including Nature, Cancer Cell, and Nature Cancer. He serves as either Global PI or Translational PI for four randomized clinical trials in breast cancer and was recently appointed Chair of the American Society of Clinical Oncology Education Committee. A/Prof Goel is also an awardee of a prestigious Snow Fellowship which will accelerate his laboratory's work from 2022 to 2030.

Victoria Gurvich

BCNA Consumer Representative

Victoria Gurvich was diagnosed with breast cancer at age 44. She underwent 18 months of active treatment, including neoadjuvant chemotherapy, surgeries, and radiation, and is still on medication. Victoria is a trained Consumer Representative (CR) for Breast Cancer Network Australia (BCNA), she is an occasional contributor to BCNA's publication The Beacon, and her areas of particular interest include cancer prevention, genetics, lymphedema, osteoporosis, and psycho-social impacts of cancer and its treatment.

A/Prof Barbara Hayes

Northern Health

Associate Professor Barbara Hayes is the Clinical Lead for Advance Care Planning at Northern Health in metropolitan Melbourne. She has a background in palliative medicine and a PhD in “Ethical CPR decision making”. Barbara has research and teaching interests in ethics and law related to end-of-life decision-making, informed consent, and shared decision making.

Dr Jolyn Hersch

The University of Sydney

Dr Jolyn Hersch is an Early Career Researcher at The University of Sydney, working at the interface between psychology and public health. She is a member of the Sydney Health Literacy Lab and the national Wiser Healthcare collaboration. Jolyn's research focuses on improving communication to support people to make better informed healthcare decisions consistent with their personal values. She is particularly interested in psychosocial aspects of screening and testing, and contexts where issues around potential overdiagnosis and overtreatment are relevant. Jolyn is currently supported by a Cancer Institute NSW fellowship to work on improving informed consent around genomic testing in oncology.

A/Prof Erin Howden

Baker Heart and Diabetes Institute

Associate Professor Erin Howden is the head of the Cardiometabolic Health and Exercise Physiology Lab and leads the Physical Activity Program at the Baker Heart and Diabetes Institute. In 2020, Erin was awarded a Heart Foundation Future Leader Fellowship to investigate the cardioprotective role of exercise in patients treated for cancer. Erin's program of research seeks to enhance the prevention and treatment of cardiometabolic disease in at risk cancer groups through developing innovative multidisciplinary approaches, with a particular focus on “exercise as medicine”. 

Safeera Hussainy

Peter MacCallum Cancer Centre

Safeera is Senior Pharmacy Research Manager at Peter MacCallum Cancer Centre, Adjunct Associate Professor at Monash University, and Honorary Principal Fellow at University of Melbourne. Recognized as the national pharmacy expert in emergency contraception, Safeera is Chief Investigator on SPHERE, an NHMRC Centre for Research Excellence in women's health, and on the MRFF ALLIANCE trial that aims to expand pharmacists’ scope of practice in contraceptive and abortion care service delivery. Safeera is also Chief Investigator on the MRFF PRECISION trial, leading the education strategy for the implementation of a pharmacogenomics program for pharmacists.

Dr Simon Hyde

Mercy Health

Dr Simon Hyde is Head of Gynaecological Oncology, Mercy Hospital for Women. He specializes in gynecological oncology, complex gynecologic surgery, colposcopy and preinvasive genital tract disease, and operative laparoscopy.

Viv Interrigi

Consumer Representative

Viv Interrigi is a mother, a partner, a daughter, a sister, and a breast cancer survivor. She was diagnosed in 2018 and went through a lumpectomy, chemotherapy, radiotherapy, infusions and has been on medications for the past 5 years. As a cancer survivor, she has had to find different ways of leaning on supports as cancer is a chronic disease that never ever completely leaves her world. She is continually using her cancer experience to volunteer as a consumer advisor – to increase the voice of the patient in decision making and to raise awareness of the importance of cancer research – to hopefully one day, have zero deaths from cancer.

Prof Michael Jefford

Peter MacCallum Cancer Centre

Professor Michael Jefford is a Consultant Medical Oncologist and Director of the Australian Cancer Survivorship Centre at Peter MacCallum Cancer Centre and is a Professorial Fellow at the University of Melbourne. His major clinical focus is on the management of people with gastrointestinal cancers; most of his research has a cancer survivorship focus. He is widely published (>220 publications at June 2023) and has presented at numerous international meetings.

A/Prof Louise Koelmeyer

Macquarie University

Associate Professor Louise Koelmeyer is the Head, Department of Health Sciences and Director of the Australian Lymphoedema Education, Research and Treatment (ALERT) program within the Faculty of Medicine, Health and Human Sciences at Macquarie University. Louise is a lymphedema therapist (occupational therapist), educator, and researcher with over 30 years of experience in both public and private settings specializing in breast cancer rehabilitation and lymphedema management. Louise is involved in strategically managing and developing the education, research, and treatment arms of the innovative and internationally recognized “Centre of Excellence” multidisciplinary program.

Prof Bogda Koczwara

Flinders Medical Centre

Professor Koczwara is a senior staff specialist in medical oncology at the Flinders Medical Centre in Adelaide, Australia and she leads the Survivorship Research Program at the Flinders University Health and Medical Research Institute. Professor Koczwara established one of the first cancer survivorship program in Australia and has contributed to key advancers in the field including survivorship epidemiology, self-management support, and the use of patient reported outcomes in cancer. She chairs the Multinational Association of Supportive Care in Cancer Psychosocial Study Group, the International Cardiooncology Society Survivorship Working Group and is the convenor of the Global Partnership on Self-management in Cancer. She co-chairs the joint Clinical Oncology Society of Australia and Cardiac Society of Australia and New Zealand Cardio-Oncology Working Group and leads a national Working Group on implementation of patient reported outcomes in cancer. She is the initiator of the Australia Asia Pacific Clinical Oncology Research Development, a collaborative of international cancer organizations aimed at improving cancer research capacity in Australia and Asia Pacific. She has been recognized as a Member of the Order of Australia for her services to oncology.

Dr Michael Krasovitsky

St Vincent's Hospital

Dr Michael Krasovitsky is a medical oncologist at St Vincent's Hospital, Sydney. He specialises in geriatric oncology, and leads both the geriatric oncology clinic and multidisciplinary team at St Vincent's Hospital. His other clinical interests include supportive care & toxicity assessment, gastrointestinal cancers, and thoracic cancers. He is the chair of the Geriatric Oncology Emerging Experts and Researchers group, a multidisciplinary collective of clinicians dedicated to geriatric oncology, and is also a proud member of the Geriatric Oncology COSA executive. Dr Krasovitsky is passionate about improving outcomes, both malignancy and quality of life related, for older individuals with cancer, and has a particular interest in tackling ageism in cancer care and health care generally.

Prof Mei Krishnasamy

Peter MacCallum Cancer Centre

Professor Mei Krishnasamy PhD, FAAN, is Director of the Academic Nursing Unit at the Peter MacCallum Cancer Centre and honorary Chair in Cancer Nursing at the University of Melbourne. She is Research and Education Lead for Nursing for the VCCC Alliance, and co-lead of the Victorian Regional Research Teaching Hub program as part of the Victorian ReVitalise initiative. Mei is past President of the Clinical Oncology Society of Australia and the Cancer Nurses of Australia and is Fellow of the American Academy of Nursing. Her research focuses on cancer supportive care, health equity and experiences of care for people with poor prognosis cancers, and the contribution of nurses to patient and system level outcomes.

Dr Heather Lane

Sir Charles Gairdner Hospital

Dr Heather Lane, MBChB, FRACP, PhD is a Consultant Geriatrician and the Director of Physician Education at Sir Charles Gairdner Hospital in Perth, where she has established a Geriatric Oncology Clinic. She is the Australian National representative for the International Society of Geriatric Oncology (SIOG), and a member of the SIOG Geriatricians Group. She is also a member of the COSA Geriatric Oncology Special Interest Group Executive.

Dr Joshua Lin

Barwon Health

Dr Joshus Lin is a breast and melanoma surgeon from Geelong, Australia, with a career journey that has taken him across every Australian state. He completed his fellowship at Sir Charles Gairdner Hospital in Perth and the Royal North Shore Hospital and Melanoma Institute Australia in Sydney. However, it was his tenure in Far North Queensland and Tasmania that shaped his current interest in regional living and work. Josh particularly enjoys the oncoplastic aspects of breast surgery and appreciates being able to extend this regionally.

Prof Geoff Lindeman

Peter MacCallum Cancer Centre and Royal Melbourne Hospital

Professor Geoff Lindeman, a clinician-scientist, is Joint Head of the Cancer Biology and Stem Cells Division at the Walter and Eliza Hall Institute. He is also a medical oncologist at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital and holds an honorary appointment as Professorial Fellow in the Department of Medicine, University of Melbourne. He established the RMH Familial Cancer Centre and was inaugural Director of the Parkville Familial Cancer Centre. His group is interested in the molecular and cellular regulators of normal mammary gland development and changes that lead to hereditary and sporadic breast cancer. The discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers has led to the international breast cancer prevention trial, BRCA-P.

A/Prof Cheng Hean Lo

Western Health

Associate Professor Cheng Hean Lo is a specialist plastic & reconstructive surgeon. He is the current Head of Department of Plastic & Reconstructive Surgery at Western Health, and is a senior medical staff at the Victorian Adult Burns Service (The Alfred). He has published at least 45 articles in peer-reviewed journals of international standing and he has been involved with successful grant and funding applications totaling in excess of $3 million. His areas of particular interest include skin tissue engineering in the setting of burn injuries, and gender affirming surgery.

Prof Sherene Loi

Peter MacCallum Cancer Centre

Professor Loi is a Medical Oncologist specialized in breast cancer treatment as well as a clinician scientist (group leader) with expertise in genomics, immunology and drug development at the Peter MacCallum Cancer Centre, Melbourne, Australia. She is recognized internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology field as well as leading international clinical trials in breast cancer immunotherapy. To date, she has published over 300 peer-reviewed research articles with a lifetime H-index of >100. Her recent work has been highly influential: she is ranked in the top 1% of highly cited researchers globally by the Web of Science. She co-chairs the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland, one of the largest global academic breast cancer trial cooperative groups. She is a current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and in 2021 received one the Prime Ministers’ Awards for Science.

Dr Stephen Luen

Peter MacCallum Cancer Centre

Dr Stephen Luen is an early career Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre specialising in breast cancer, sarcoma, early drug development, and precision oncology. In 2021, he completed a PhD supervised by Professor Sherene Loi investigating genomic and immune biomarkers in early-stage breast cancers, and continues to work closely with the laboratory. His current research interests include the study of genomic and immune biomarkers in high-risk and treatment-refractory breast cancers, the development of novel clinical trial approaches for high-risk breast cancers, and the early phase development of new therapeutic compounds.

Jodie Lydeker

BCNA Consumer Representative

Jodie Lydeker is a lawyer by training and has spent over 20 years in the public sector leading national and state-wide social policy reforms in the areas of criminal justice, education, mental health and anti-corruption. But a diagnosis of invasive breast cancer 5 years ago at the age of 40 carved out a new pathway into public health. After being part of the Victorian Government's COVID-19 response and a brief stint in Canberra leading national mental health reforms for the Australian Department of Health, Jodie is now the managing director of her own policy and project management company. Outside of work, Jodie is a proud consumer representative with BCNA, Cancer Council Victoria, Genesis Care and the Psycho-oncology Co-operative Research Group (PoCoG) at the University of Sydney. In addition to qualifications in law and business, she has studied psychosocial oncology and service navigation to help advocate for improved availability of integrative care models that prioritise emotional health and wellbeing for people impacted by cancer. She is currently writing her book called ‘Strong Enough to Break’ that reflects on her experiences of both cancer and mental illness to encourage people to give themselves permission to pause.

A/Prof Brigid Lynch

Cancer Council Victoria, University of Melbourne

Associate Professor Brigid Lynch is a cancer epidemiologist whose research focuses on how physical activity is associated with cancer risk, biological mechanisms underlying risk, and health outcomes for cancer survivors. Her research interests include applying causal inference methods to help advance the field of physical activity epidemiology. Brigid is a Principal Investigator of the Australian Breakthrough Cancer Study, an ongoing cohort study of over 50,000 Australians investigating the role that genes, lifestyle, and environment play in the development of cancer and other diseases.

Prof Bruce Mann

Victorian Comprehensive Cancer Centre

Professor Bruce Mann is Director of the Breast Tumour Stream of the Victorian Comprehensive Cancer Centre. He is also Director of Research at Breast Cancer Trials – Australia and New Zealand's cooperative breast cancer clinical trials organization. His interests relate to systems for optimal breast cancer care and research to improve early diagnosis and tailor the extent of breast cancer treatment to the individual patient.

A/Prof Forbes McGain

Western Health, University of Melbourne

Associate Professor Forbes McGain is an anesthetist and intensive care physician at Western Health, Melbourne, Australia, and Associate Dean, Sustainable Healthcare, University of Melbourne. Forbes enjoys research, teaching, and education at the hospital, university, and beyond. During COVID-19 Forbes received the Clunies Ross Award for co-creating the patented McMonty personal isolation hood to protect healthcare workers. Collaboratively, Forbes is now embarking upon further innovative solutions to make healthcare more sustainable. He is a co-lead on the Lancet Commission for Sustainable Healthcare.

Dr Alexandra Murphy

Victorian Heart Hospital and Austin Health

Dr Alexandra Murphy graduated from the University of Melbourne with a Bachelor of Medicine/Bachelor of Surgery and Bachelor of Medical Science. She entered the Cardiology Advanced Training program at the Austin Hospital following which she became a Fellow of the Royal Australasian College of Physicians (FRACP). Alex has completed advanced fellowships in cardiac imaging, imaging for structural intervention, and cardio-oncology. Dr Murphy's PhD focuses on the optimization of cardiovascular outcomes in cancer patients and was supported by scholarships from the NHMRC, National Heart Foundation and Cardiac Society of Australia and New Zealand. The centerpiece of her research was the SMART-BREAST randomized controlled trial which demonstrated the efficacy of her patented smartphone application BreastMate in the exercise promotion and cardiovascular risk reduction of early stage breast cancer patients. From this she was awarded a Fulbright Scholarship to continue her research at Mount Sinai Hospital in New York City. Dr Murphy is now a cardio-oncologist at the newly established Victorian Heart Hospital and Austin Health.

Naveena Nekkalapudi

BCNA Consumer Representative

Following her diagnosis of triple negative breast cancer and the subsequent treatment, Naveena decided to re-evaluate her life and focus on matters that are important to her. She describes it as changing from being career ambitious to being life ambitious, that is, wanting to utilize her varied skills and knowledge in assisting others to achieve better health outcomes. In her previous (corporate) life, she was a senior professional with extensive strategy, research, M&A, and management skills across a range of industries – dairy, trustee, funds management, and private health insurance. Naveena has an M. B. A. from Melbourne Business School and is a consumer representative of BCNA, Cancer Council Victoria, Breast Cancer Trials, VCCC, and Walter and Eliza Hall Institute of Medical Research to name a few.

Kerry Patford

McGrath Foundation

With 20 years of Breast Care Nurse experience, Kerry has a special interest in accessible and equitable care in regional and rural areas. A McGrath Breast Care Nurse since 2009, more recently Kerry has worked with the McGrath Foundation in developing the Model of Care, with the original version released in 2019, and the reviewed Model of Care for Early Breast Cancer released in 2023. Sharing her time now within the clinical space of her McGrath BCN role, Kerry works within a team of Clinical Leaders at the McGrath Foundation.

Dr Elizabeth Pearson

Peter MacCallum Cancer Centre

Dr Elizabeth Pearson is an occupational therapist and allied health researcher working at the Peter MacCallum Cancer Centre in Melbourne, Australia. Her main goal in both roles has been to help people with cancer live their lives as well as possible, for as long as possible.

Elizabeth's recent research has explored the feasibility of implementing evidence-based guidelines and stepped-care cognitive behavior therapy to address the common problem of cancer-related fatigue.

A/Prof Michelle Peate

University of Melbourne

Associate Professor Michelle Peate is the Program Leader for the Psychosocial Health and Wellbeing Research (emPoWeR) Unit, University of Melbourne. She was a 2011 NSW Young Tall Poppy from the Australian Institute for Policy in Science and 2017 International Psycho-Oncology Society New Investigator Award winner. She is President of the Australian Society of Obstetrics and Gynaecology and sits on several clinical guideline committees and advisory panels, including the COSA fertility preservation guideline committee. Her main goal is to develop evidence-based interventions that improve patient experiences at the intersection of cancer, reproductive health, and psychology.

Dr Melanie Plinsinga

Menzies Health Institute

Dr Melanie Plinsinga is an early career researcher in the field of symptom research, with particular interest in exercise management and rehabilitation. Her current work uses her expertise to address unanswered questions in cancer-related pain and lymphedema to improve lives through the prevention and better management of survivorship symptoms.

Hildegard Reul-Hirche

Royal Brisbane and Women's Hospital

Ms Reul-Hirche has been an honorary Research Fellow at the Physiotherapy Department at the Royal Brisbane and Women's Hospital (RBWH) since April 2019. She is a physiotherapist with over 30 years of clinical experience treating lymphedema. Ms Reul-Hirche is the founder, curriculum leader, and co-facilitator of Lymphoedema Training Modules accredited by the Australasian Lymphology Association (ALA) and presented at RBWH. She is an accredited lymphedema therapist with the ALA and a titled lymphedema physiotherapist under the Australian Physiotherapy Association. At present she is completing her MPhil at Griffith University (Nathan).

Gail Rowan

Peter MacCallum Cancer Centre

Gail's main area of practice and interest includes the treatment of hematological malignancies, minimization of anti-cancer therapy related adverse effects and education on the safe use of anti-cancer therapies especially oral therapies. Gail is past chair and a current committee member of the Cancer Pharmacists Group (CPG) of COSA, and a member of the Leadership Committee of the SHPA Oncology & Haematology Specialty Practice Group, and is qualified as a Board Certified Oncology Pharmacist (BCOP) through the Board of Pharmaceutical Specialities in the United States.

Prof Christobel Saunders

University of Melbourne, Royal Melbourne Hospital, Peter MacCallum Cancer Institute

Professor Christobel Saunders AO, MB BS, FRCS, FRACS, FAAHMS is the James Stewart Chair of Surgery, the Head of the Department of Surgery at the University of Melbourne (Royal Melbourne Hospital precinct), Director of Medical Research at Melbourne Medical School, and consultant surgeon in the Department of General Surgery at Royal Melbourne Hospital and the Peter MacCallum Cancer Institute. Christobel is internationally recognized as one of Australia's most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research, including clinical trials of new treatments, and psychosocial, translational, and health services research. In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honors including the Order of Australia 2018, the Uccio Querci della Rovere Award (2018), WA Women's Hall of Fame Inductee (2018), WA Scientist of the Year (2017), Cancer Council WA Career Achievement Award (2021) and was elected to the Australian Academy of Health and Medical Science in 2016. She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer. In the past 5 years, Christobel has published over 200 peer-reviewed journal articles. She sits on the boards of several health and research organizations including as Vice-President for All.Can International and on the boards of All.Can Australia, Breast Cancer Trials, the Australian Centre for Value-Based Health Care and PathWest. Christobel is closely involved in strategic planning and management of health and cancer services in Australia including being a member of the Medicare Review Advisory Committee, panel member of the Medical Services Advisory Committee, past President of the Breast Surgical Society of ANZ, and past Advisory Council member of Cancer Australia. She was the Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine.

Dr Peter Savas

Peter MacCallum Cancer Centre

Dr Peter Savas is a medical oncologist, clinical trial investigator, and clinician scientist specializing in breast cancer. With broad interests in breast cancer genomics, the immune microenvironment, and applications of artificial intelligence in histology, Dr Savas’ current work is focused on enabling precision oncology approaches in advanced and early stage breast cancer, and the use of single cell methods to interrogate the immune response to invasive breast cancer.

A/Prof Camille Short

University of Melbourne

Associate Professor Camille Short is behavioral scientist and Victoria Cancer Agency Mid-Career Fellow. She works at the University of Melbourne within the Melbourne Centre for Behaviour Change and the CanRex Exercise and Recovery Research Group. Camille has experience and training in health psychology, digital, and public health. She leads a program of work focused on the use of technology for improving access to high quality, personalized, and multidisciplinary exercise support for cancer patients. As a behavioral scientist, she is passionate about ensuring exercise programs support people to make lifestyle changes by addressing the psychological, physical, and social factors that impact on exercise and access to exercise services. Camille's research has influenced policy and practice within Australian health services and is widely cited internationally.

Dr Olivia Smibert

Peter Mac Callum Cancer Center, University of Melbourne

Dr Smibert is an infectious diseases clinician at Austin Health and PhD student at the Peter Mac Callum Cancer Center and University of Melbourne. In 2019 she completed a fellowship at Massachusetts General Hospital, Harvard University in transplant infectious diseases.

She has earned a number of awards including the 2019 NHMRC Gustav Nossal Postgraduate Scholarship Award, an International investigator Award from the Infectious Diseases Society of America, an American Society of Transplant Fellows Award, and the RACP Richard Kemp Memorial Fellowship. She has contributed to over 49 peer-reviewed publications and is undertaking her PhD at the Peter MacCallum Cancer Centre through the Department of Oncology. Her PhD project aims to define the role of the microbiome in determining infectious and immunological outcomes in immune compromised specialty patient populations and how this could lead to novel therapeutics and diagnostics.

Dr David Speakman

Peter MacCallum Cancer Centre

Dr David Speakman is a Surgeon specializing in Breast Disease and Melanoma. He has over 20 years sub-specialist experience in these areas. Dr Speakman is particularly interested in the minimally invasive treatment of breast cancer involving breast conservation, oncoplastic techniques, sentinel node biopsy, and neo-adjuvant therapies. He was trained in breast reconstructive techniques as a Fellow and also works closely with dedicated Breast Plastic and Reconstructive Surgeons. He is also widely experienced in benign Breast Disease. He has had a long involvement with the breast screening program through assessment clinics as well as on the Scientific Advisory Committee of BreastScreen Victoria. Dr Speakman is active in clinical trial programs, in particular the large Z11 Trial in breast cancer and the MSLT II in melanoma. These are both international trials. He has taught medical students from both Melbourne and Monash Universities for the past 20 years. Communication in cancer care is critical. Dr Speakman has taught the “Breaking Bad News” communication skills course for clinicians at The Royal College of Surgeons for the past 10 years. Dr Speakman is the Chief Medical Officer and Executive Director Medical Services at the Peter MacCallum Cancer Centre and is a Senior Surgeon in both the Breast and Skin and Melanoma Units there. Dr Speakman believes that a strong connection between the patient and their entire treating team is vital in getting the best outcomes for patients with cancer.

A/Prof Kate Stern

Royal Women's Hospital

Associate Professor Kate Stern is Associate Professor of Obstetrics and Gynaecology at the University of Melbourne, Royal Women's Hospital. Kate is the Head of Reproductive Services at the Royal Women's Hospital, Melbourne and Clinical Director and Head of Clinical Research at Melbourne IVF. She co-chaired the COSA Fertility Preservation Guidance Committee. Kate is a fertility specialist, gynecologist, and reproductive endocrinologist and her special interest is in medical fertility preservation. She received the award of the Order of Australia in 2022.

Dr Wendy Vanselow

Royal Women's Hospital

Dr Wendy Vanselow is Head of Psychosexual Medicine at RWH. She has a background in General Practice and a PhD in psychiatry. She studied sexual medicine at Oxford University and became an inaugural Fellow of the European Committee for Sexual Medicine in 2012. At RWH she also consults in the Menopause after Cancer clinic.

A/Prof Lisa Whop

The Australian National University

Associate Professor Lisa Whop is a Gumulgal woman from the Wagadagam tribe of Mabuiag Island in the Torres Strait and is Australia's leading authority on cervical cancer control in Aboriginal and Torres Strait Islander women. Lisa is an Indigenist epidemiologist with experience in implementation health research to develop, inform, and change public health policy, guidelines, and practice. She holds a National Health and Medical Research Council Investigator Grant and is the lead of the cervical cancer elimination team in the National Centre for Aboriginal and Torres Strait Islander Wellbeing Research at the Australian National University. She is incoming Chair of the Cancer Australia Aboriginal and Torres Strait Islander Leadership Committee on Cancer Control.

Dr Joshua Wiley

Monash University

Dr Joshua Wiley is a behavioral medicine researcher working at Monash University and the Peter MacCallum Cancer Centre with a focus on understanding and improving sleep and mental health in people after cancer. His research has resulted in >100 publications and >$10 million in grant funding from both national and international agencies. His research has two main tracks: one focused on foundational knowledge gain such as understanding functions, trajectories, and correlates of sleep and mental health and the second focused on designing and evaluating brief, scalable interventions to improve sleep and mental health, often using digital and telehealth methods in randomized clinical trials.

Dr Aaron Wong

Peter McCallum Cancer Centre, The Royal Melbourne Hospital

Dr Aaron K Wong is a dual trained Palliative Care Physician and Medical Oncologist and Early Career Researcher. Aaron established the Palliative Care Clinical Trials Unit at Olivia Newton John Cancer and Wellness Centre (2018) and is currently Clinical Trials Lead at the Peter MacCallum Cancer Centre, and The Royal Melbourne Hospital. Aaron has been Chief Investigator on several palliative care clinical trials. He is completing a PhD supported by an NHMRC Postgraduate Scholarship focusing on investigating biomarkers using pharmacogenomics, for optimal selection of opioids for optimal pain control.

Dr Felicity Wright

Department of Health

Dr Felicity Wright is the Director of Pharmacy at Sydney Children's Hospital, Randwick and a Net Zero Clinical Lead for the Sydney Children's Hospital Network (SCHN). Felicity is a paediatric oncology and cellular therapy pharmacist by background, a Board-Certified Oncology Pharmacist (USA) with a PhD in pharmacogenetics and a Master of Public Health in health policy. Her recent health system research in decarbonisation adds carbon metrics to quality improvement and valued based care initiatives delivering measurable carbon reduction in clinical care, waste management and pharmaceutical procurement.

国家发言人。
George Au-Yeung博士Peter MacCallum癌症中心George Au-Yeung博士是Peter MacCallam癌症中心的临床医生,对癌症的分子生物学有研究兴趣,并进行新的生物标志物驱动的临床试验和转化研究。他在David Bowtell教授的实验室完成了博士学位,研究了细胞周期蛋白E1扩增的高级别浆液性癌症的新治疗策略,这是一种表现激进且缺乏治疗选择的卵巢癌。他现在是Peter Mac的全职肿瘤医生,负责妇科肿瘤和黑色素瘤服务,也是肿瘤医学联合副主任。他是ANZGOG的活跃成员,在澳大利亚皇家医师学院(RACP)和澳大利亚医学肿瘤集团(MOGA)担任现任和前任职务。Kira BloomquistGriffith大学、加州大学旧金山分校、哥本哈根大学医院我是一名物理治疗师和研究员,目前隶属于大学医院健康研究中心(UCSF),丹麦Rigshospitalet哥本哈根大学医院和格里菲斯大学昆士兰孟席斯健康研究所。我感兴趣的主要领域涉及“癌症幸存者”,并借鉴了自1999年以来作为物理治疗师与癌症幸存者的个人实践经验,以及自2003年以来在担任各种研究角色(如数据收集员、研究助理和主要研究员)时获得的经验。我的专业知识涉及了解癌症后面临的身体和心理问题,特别是淋巴水肿,以及运动在癌症恢复中的作用。澳大利亚癌症协会副教授Anna Boltong是癌症澳大利亚癌症控制战略处处长。Anna是一名经过培训的营养师,她的背景涵盖了临床肿瘤学、支持性护理研究、政策制定、健康不平等和教育领域的国内外领导地位。在癌症澳大利亚,Anna负责监督澳大利亚癌症计划以及最佳护理系统和土著癌症控制组合的制定和实施。Angie BoneMonash大学Angie教授是莫纳什可持续发展研究所行星健康实践副教授,她专注于卫生部门韧性和可持续性、行为变化和行星健康的系统转型。她是维多利亚州的高级公共卫生医生和前副首席卫生官,拥有超过15年的公共卫生领导和环境对健康和健康公平影响的研究经验。Angie在研究/政策/实践界面上与一系列学科合作,提供公共卫生技术专业知识,并结合政策和实施经验,以加强气候变化对健康影响的证据和减少风险的干预措施,包括应对更广泛的、,影响健康和福祉受到损害的可能性和严重程度的“上游”因素。安吉与人合著了40多篇同行评审文章和书籍章节,并在国内外许多关于气候变化、可持续性和健康的论坛上发表了演讲。Julia Brotherton教授墨尔本大学Julia Brother ton教授是墨尔本大学墨尔本人口与全球卫生学院的公共卫生医师、流行病学家和癌症预防政策与实施教授。她还是国家免疫研究和监测中心的教授研究员。15年来,Julia一直参与研究和政策制定,为HPV疫苗接种和宫颈筛查计划的实施和评估提供信息。她是CHIC全球HPV疫苗理事会的联合主席,也是NHMRC癌症控制卓越研究中心(CRE)和NHMRC改善澳大利亚原住民和托雷斯海峡岛民癌症服务的靶向方法中心(TACTICS)的CI,悉尼大学教授Karen Canfell是水仙花中心的首任主任,该中心是悉尼大学的旗舰中心,也是与澳大利亚新南威尔士州癌症委员会的合资企业。她还是一名教授;悉尼大学医学与健康学院NHMRC领导力研究员。她的研究涉及癌症控制新策略的评估和翻译,她领导了澳大利亚和国际政府机构的多项影响和经济评估。例如,她的工作支持了澳大利亚国家宫颈筛查计划的转变,该计划于2017年转向HPV DNA检测,以取代巴氏涂片,水仙花中心团队一直积极参与癌症筛查的评估。 她积极参与全球卫生工作,其团队的工作为2020年世界卫生组织消除癌症战略计划的影响和投资案例奠定了基础;在2020-2021年期间,她的团队支持世界卫生组织制定低收入国家宫颈筛查的详细临床管理指南。2020年,她与国际癌症研究机构(IARC)的Freddie Bray博士、与主要合作伙伴IARC的癌症系统复原力国际伙伴关系(I-PaRCS)、国际癌症筛查网络、加拿大抗击癌症伙伴关系和水仙花中心共同发起并共同领导。I-PaRCS致力于支持癌症控制决策,在新冠肺炎大流行期间和之后。Stefanie Carino博士气候与健康联盟Stefanie Carino博士是气候与健康协会的可持续医疗保健项目经理,负责协调太平洋地区的全球绿色健康医院。她完成了环境可持续食品服务的博士学位,还在一家公立医院担任可持续食品系统营养师。Jordan CaseyWestern HealthJordan Casey是原住民健康、政策和;西部健康规划。约旦负责监督Wilim Berrbang(原住民卫生部门),并负责实施西部原住民健康文化安全计划。约旦热衷于将文化安全纳入主流医疗服务。Wanda CuiPeter MacCallum癌症中心Wanda Cui博士是Peter MacCallum癌症中心的医学肿瘤学家,也是墨尔本大学的博士生,对肿瘤生育和妊娠期癌症特别感兴趣。她最近刚从皇家马斯登医院的一个研究所回来。她的研究重点是提高我们对癌症治疗对生育能力和卵巢功能影响的理解。A.Stephen David教授Peter MacCallum癌症中心协会教授Steven David是Icon癌症中心Mulgrave和PeterMac的放射肿瘤学家。大卫教授毕业于西澳大利亚大学,并在墨尔本的彼得·麦卡勒姆癌症中心完成了他的专家培训。随后,他担任了癌症乳腺癌和肺癌亚专家的职位。Steven是许多由研究者发起的地方、国家和多中心临床试验的首席研究员。他目前的研究领域包括开发和实施深度吸气屏息技术,以减少左侧乳腺癌症患者的心脏辐射,以及使用高剂量精确辐射(SABR)治疗少转移性疾病患者。Rachel Delahunty医生女性慈善医院、Peter MacCallum癌症中心、吉隆大学医院Rachel Drahunty博士是女性慈善医院(The Mercy Hospital for Women)、Peter MacCallum癌症中心和吉隆大学医院的医学肿瘤学家,对妇科肿瘤学、转化和临床研究特别感兴趣。Rachel最近通过墨尔本大学和Peter MacCallum癌症中心获得了博士学位,该中心题为“通过预防降低癌症的发病率和死亡率,包括领导卵巢癌症预防项目“TRACEBACK””昆士兰大学癌症和健康研究项目。Diaz博士目前正与她的团队和合作者合作,调查被诊断为癌症的原住民和托雷斯海峡岛民的心血管风险、护理和经验。作为这项工作的一部分,Diaz博士正在与一个由受癌症影响的原住民和托雷斯海峡岛民组成的咨询小组合作,该小组确定了共同设计文化响应性心脏病生态资源的必要性。Polly Dufton墨尔本大学/奥斯汀健康Polly博士是Olivia Newton John癌症研究与健康中心的注册护士,曾担任过多个临床和支持性护理角色。她目前正在墨尔本大学攻读博士学位,研究癌症患者在急诊科接受门诊癌症治疗的情况。Ben Felmingham皇家儿童医院Ben Felminghan先生是一名儿科药剂师,在墨尔本皇家儿童医院(RCH)完成了药学培训。然后,他继续专注于儿科肿瘤学,在包括骨髓移植在内的所有癌症儿科流方面,他拥有超过10年的经验。2021年,在澳大利亚心脏肿瘤注册中心(ACOR)的研究工作下,本领导了有史以来第一份儿科心脏肿瘤指南的制定。他已经实施并协调了位于RCH的多学科心肿瘤诊所。 她是悉尼健康素养实验室和全国Wiser Healthcare合作组织的成员。Jolyn的研究重点是改善沟通,支持人们做出更明智的、符合个人价值观的医疗保健决策。她对筛查和检测的心理社会方面以及潜在的过度诊断和过度治疗相关问题特别感兴趣。Jolyn目前得到癌症研究所新南威尔士州研究金的支持,致力于改善肿瘤学基因组检测的知情同意。A/Prof Erin Howden贝克心脏和糖尿病研究所助理教授Erin Howdon是心脏代谢健康和运动生理学实验室的负责人,并领导贝克心脏与糖尿病研究所的体育活动项目。 2020年,Erin获得了心脏基金会未来领导者奖学金,以研究运动对癌症患者的心脏保护作用。Erin的研究计划旨在通过开发创新的多学科方法,加强癌症高危人群心脏代谢疾病的预防和治疗,特别关注“运动即医学”。 Safeera HussainyPeter MacCallum癌症中心Safeera是Peter MacCallum癌症中心的高级药学研究经理、莫纳什大学兼职副教授和墨尔本大学名誉首席研究员。Safeera被公认为紧急避孕方面的国家药学专家,是NHMRC妇女健康卓越研究中心SPHERE和MRFF联盟试验的首席研究员,该试验旨在扩大药剂师在避孕和堕胎护理服务提供方面的执业范围。Safeera还是MRFF PRECISION试验的首席研究员,领导实施药剂师药物基因组学计划的教育战略。Simon HydeMercy HealthSimon Hyde医生是Mercy妇女医院妇科肿瘤科主任。他擅长妇科肿瘤学、复杂妇科手术、阴道镜检查和侵袭前生殖道疾病以及腹腔镜手术。Viv InterrigiConsumer Representative Interrigi是一位母亲、伴侣、女儿、姐姐和癌症幸存者。她于2018年被确诊,接受了肿块切除术、化疗、放疗和输液,在过去的5年里一直在服药。作为一名癌症幸存者,她不得不找到不同的方式来依靠支持,因为癌症是一种慢性病,永远不会完全离开她的世界。她不断利用自己在癌症方面的经验志愿担任消费者顾问,以增加患者在决策中的发言权,并提高人们对癌症研究重要性的认识,希望有一天癌症的死亡人数为零。Michael Jefford教授Peter MacCallum癌症中心教授Michael Jefford是医学肿瘤顾问和Peter MacCallumnenenebc癌症中心澳大利亚癌症幸存者中心主任,也是墨尔本大学的教授。他的主要临床重点是胃肠道癌症患者的治疗;他的大部分研究都以癌症生存为重点。他被广泛出版(截至2023年6月,出版了220本),并在许多国际会议上发表了演讲。麦考瑞大学Louise Koelmeyer教授Louise Koolmeyer副教授是麦考瑞大学医学、健康与人文科学学院健康科学系主任兼澳大利亚淋巴水肿教育、研究与治疗(ALERT)项目主任。Louise是一名淋巴水肿治疗师(职业治疗师)、教育家和研究员,在公共和私人环境中拥有超过30年的经验,专门从事乳腺癌症康复和淋巴水肿管理。Louise参与了创新和国际公认的“卓越中心”多学科项目的教育、研究和治疗部门的战略管理和发展。Bogda Koczwara教授是澳大利亚阿德莱德弗林德斯医学中心的高级肿瘤学专家,她领导着弗林德斯大学健康与医学研究所的幸存者研究项目。Koczwara教授在澳大利亚建立了第一个癌症生存计划,并为该领域的关键进步做出了贡献,包括生存流行病学、自我管理支持和癌症患者报告结果的使用。她是癌症心理社会研究小组多国支持性护理协会主席、国际心脏肿瘤学会幸存者工作组主席,也是癌症自我管理全球伙伴关系的召集人。 Sherene LoiPeter MacCallum癌症中心Loi教授是一位专门研究癌症治疗的医学肿瘤学家,也是澳大利亚墨尔本Peter MacCallum癌症中心的一位在基因组学、免疫学和药物开发方面拥有专业知识的临床医生(组长)。她被国际公认为领先的临床医生科学家,其工作为乳腺癌症免疫学领域带来了新的见解,并在癌症免疫疗法方面进行了领先的国际临床试验。到目前为止,她已经发表了300多篇同行评审的研究文章,终身H指数&gt;100.她最近的工作非常有影响力:她在《科学网》全球被高度引用的研究人员中排名前1%。她是总部设在瑞士伯尔尼的国际癌症研究小组(IBCSG)的联合主席,该小组是全球最大的癌症学术试验合作小组之一。她是澳大利亚首届癌症国家乳腺基金会(NBCF)的现任主席,并于2021年获得了一项总理科学奖。Stephen Luen博士Peter MacCallum癌症中心Stephen Lun博士是Peter MacCall勒姆癌症中心的早期医学肿瘤学家和转化研究员,专门研究癌症、肉瘤、早期药物开发和精准肿瘤学。2021年,他完成了由Sherene Loi教授指导的博士学位,研究早期乳腺癌的基因组和免疫生物标志物,并继续与实验室密切合作。他目前的研究兴趣包括研究高风险和难治性乳腺癌的基因组和免疫生物标志物,开发高风险乳腺癌的新临床试验方法,以及早期开发新的治疗化合物。Jodie LydekerBCNA消费者代表Jodie Lydeker是一名受过培训的律师,在公共部门工作了20多年,领导刑事司法、教育、心理健康和反腐败领域的国家和全州社会政策改革。但5年前,40岁的癌症被诊断为侵袭性乳腺癌,为公共卫生开辟了新的途径。朱迪是维多利亚州政府新冠肺炎应对措施的一部分,曾在堪培拉短暂领导澳大利亚卫生部的国家心理健康改革,现在是她自己的政策和项目管理公司的总经理。在工作之外,朱迪是BCNA、癌症维多利亚委员会、Genesis Care和悉尼大学心理生态学合作研究小组(PoCoG)的骄傲消费者代表。除了法律和商业资格外,她还学习了心理社会肿瘤学和服务导航,以帮助倡导改善综合护理模式的可用性,这些模式优先考虑受癌症影响的人的情绪健康和福祉。她目前正在写一本名为《坚强到可以崩溃》的书,这本书反映了她患癌症和精神疾病的经历,鼓励人们允许自己停下来。布里吉德·林奇教授墨尔本大学维多利亚癌症委员会布里吉德·林奇副教授是癌症流行病学家,其研究重点是身体活动如何与癌症风险、潜在风险的生物学机制以及癌症幸存者的健康结果相关。她的研究兴趣包括应用因果推断方法来帮助推进体育活动流行病学领域。布里吉德是澳大利亚癌症突破研究的首席研究员,该研究正在对50000多名澳大利亚人进行队列研究,研究基因、生活方式和环境在癌症和其他疾病发展中的作用。Bruce Mann教授维多利亚癌症综合中心Bruce Man教授是维多利亚癌症综合中心乳腺肿瘤流主任。他还是癌症试验的研究主任——澳大利亚和新西兰癌症临床试验合作组织。他的兴趣涉及癌症最佳护理和研究系统,以改善早期诊断并根据患者个体定制癌症治疗范围。A/Prof Forbes McGain墨尔本大学西部健康中心副教授Forbes McKain是澳大利亚墨尔本西部健康中心的麻醉师和重症监护医生,也是墨尔本大学可持续医疗中心的副院长。福布斯喜欢在医院、大学和其他地方从事研究、教学和教育。在新冠肺炎期间,福布斯因共同创建了获得专利的麦克蒙蒂个人隔离帽以保护医护人员而获得了Clunies Ross奖。通过合作,《福布斯》正在着手进一步创新解决方案,使医疗保健更加可持续。他是柳叶刀可持续医疗委员会的联合负责人。 Gail RowanPeter MacCallum癌症中心Gail的主要实践和兴趣领域包括血液系统恶性肿瘤的治疗、尽量减少抗癌治疗相关的不良影响以及安全使用抗癌疗法(尤其是口服疗法)的教育。Gail是COSA癌症药剂师小组(CPG)的前任主席和现任委员会成员,也是SHPA肿瘤学&amp;血液学专业实践小组,并通过美国药学专业委员会获得委员会注册肿瘤药剂师(BCOP)资格。Christobel Saunders墨尔本大学皇家墨尔本医院Peter MacCallum癌症研究所教授Christobel Sauders AO,MB BS,FRCS,FRACS,FAAHMS是James Stewart外科主席,墨尔本大学(皇家墨尔本医院区)外科主任,墨尔本医学院医学研究主任,以及皇家墨尔本医院普通外科和癌症研究所的外科医生顾问。克里斯托贝尔是国际公认的澳大利亚最杰出的癌症研究外科医生之一。她为癌症研究做出了重大贡献,包括新疗法的临床试验,以及心理社会、转化和健康服务研究。为了表彰Christobel持续的职业卓越和创新,她通过多项奖项和荣誉获得了公众认可,包括2018年澳大利亚勋章、2018年Uccio Querci della Rovere奖、2018年WA女子名人堂入选者、2017年WA年度科学家,癌症理事会WA职业成就奖(2021年),并于2016年入选澳大利亚卫生与医学科学院。她为&gt;30年评估早期乳腺癌症治疗的疗效和实用性。在过去的5年里,Christobel发表了200多篇经过同行评审的期刊文章。她是多个健康和研究组织的董事会成员,包括担任全民副主席。Can International和All董事会成员。Can Australia,乳腺癌症试验,澳大利亚基于价值的医疗保健中心和PathWest。Christobel密切参与澳大利亚健康和癌症服务的战略规划和管理,包括医疗保险审查咨询委员会成员、医疗服务咨询委员会小组成员、澳新银行乳腺外科学会前任主席和癌症澳大利亚咨询委员会前任成员。她是国家卫生服务提供者PathWest实验室医学的首任主席。Peter SavasPeter MacCallum癌症中心Peter Savas博士是一位专门研究癌症的医学肿瘤学家、临床试验研究员和临床医生。由于对乳腺癌症基因组学、免疫微环境和人工智能在组织学中的应用有着广泛的兴趣,Savas博士目前的工作重点是在晚期和早期癌症乳腺癌中实现精确肿瘤学方法,并使用单细胞方法询问对侵袭性癌症的免疫反应。Camille Short教授墨尔本大学Camille肖特副教授是行为科学家和维多利亚癌症机构Mid-Career研究员。她在墨尔本大学墨尔本行为改变中心和CanRex运动与恢复研究小组工作。Camille拥有健康心理学、数字和公共卫生方面的经验和培训。她领导了一项工作计划,重点是利用技术改善癌症患者获得高质量、个性化和多学科运动支持的机会。作为一名行为科学家,她热衷于确保锻炼计划通过解决影响锻炼和获得锻炼服务的心理、身体和社会因素,支持人们改变生活方式。卡米尔的研究影响了澳大利亚卫生服务部门的政策和实践,并在国际上被广泛引用。Olivia SmibertPeter Mac Callum癌症中心,墨尔本大学Smibert博士是Austin Health的传染病临床医生,也是Peter Mac Callum癌症中心和墨尔本大学的博士生。2019年,她在哈佛大学马萨诸塞州总医院完成了移植传染病研究。她获得了多项奖项,包括2019年NHMRC Gustav Nossal研究生奖学金奖、美国传染病学会国际研究员奖、美国移植学会研究员奖和RACP Richard Kemp纪念奖学金。她为超过49篇同行评议的出版物做出了贡献,并通过肿瘤科在癌症中心获得博士学位。 她的博士项目旨在确定微生物组在确定免疫受损专业患者群体的感染和免疫结果中的作用,以及这如何导致新的治疗和诊断。David SpeakmanPeter MacCallum癌症中心David Speakman博士是一名专门研究乳腺疾病和黑色素瘤的外科医生。他在这些领域拥有超过20年的副专家经验。Speakman博士对癌症的微创治疗特别感兴趣,包括乳腺保护、肿瘤整形技术、前哨淋巴结活检和新辅助疗法。他作为研究员接受过乳房重建技术培训,还与专门的乳房整形和重建外科医生密切合作。他在乳腺良性疾病方面也有丰富的经验。他通过评估诊所以及维多利亚州乳腺筛查科学咨询委员会长期参与乳腺筛查项目。Speakman博士积极参与临床试验项目,特别是癌症的大型Z11试验和黑色素瘤的MSLT II试验。这两项都是国际试验。在过去的20年里,他教过墨尔本大学和莫纳什大学的医学生。癌症护理中的沟通至关重要。在过去的10年里,Speakman博士一直在皇家外科学院为临床医生教授“突发坏消息”沟通技能课程。Speakman博士是Peter MacCallum癌症中心的首席医疗官和医疗服务执行主任,也是该中心乳腺、皮肤和黑色素瘤科的高级外科医生。Speakman博士认为,患者和整个治疗团队之间的紧密联系对于癌症患者获得最佳结果至关重要。A/Prof Kate SternRoyal女子医院副教授Kate Stern是墨尔本大学皇家女子医院妇产科副教授。凯特是墨尔本皇家女子医院生殖服务负责人,也是墨尔本试管婴儿的临床主任和临床研究负责人。她是COSA生育保护指导委员会的联合主席。凯特是一名生育专家、妇科医生和生殖内分泌学家,她对医学生育保护特别感兴趣。她于2022年获得澳大利亚勋章。Wendy Vanselow医生皇家女子医院Wendy Vanselow医生是RWH的性心理医学负责人。她拥有全科医学背景和精神病学博士学位。她在牛津大学学习性医学,并于2012年成为欧洲性医学委员会首届研究员。在RWH,她还为癌症后更年期诊所提供咨询。澳大利亚国立大学副教授Lisa Whop是一名来自托雷斯海峡马比亚格岛Wagadagam部落的Gumulgal妇女,是澳大利亚控制土著和托雷斯海峡岛民宫颈癌症的主要权威。Lisa是一位Indigenist流行病学家,在实施健康研究以制定、告知和改变公共卫生政策、指南和实践方面具有丰富经验。她拥有国家卫生和医学研究委员会调查员补助金,是澳大利亚国立大学国家土著和托雷斯海峡岛民福利研究中心癌症消除小组的负责人。她即将担任癌症澳大利亚土著和托雷斯海峡岛民癌症控制领导委员会主席。Joshua Wiley博士莫纳什大学Joshua Willey博士是莫纳什大学和Peter MacCallum癌症中心的行为医学研究员,专注于了解和改善癌症患者的睡眠和心理健康。他的研究已经导致&gt;100份出版物和&gt$来自国家和国际机构的1000万赠款。他的研究有两个主要方向:一个方向专注于基础知识的获取,如理解睡眠和心理健康的功能、轨迹和相关性,另一个方向则专注于设计和评估简短、可扩展的干预措施,以改善睡眠和心理健康,通常在随机临床试验中使用数字和远程健康方法。Aaron WongPeter McCallum博士皇家墨尔本医院癌症中心Aaron K Wong博士是一名接受过双重培训的姑息治疗医师、医学肿瘤学家和早期职业研究员。Aaron在Olivia Newton John癌症和健康中心成立了姑息治疗临床试验室(2018年),目前是Peter MacCallum癌症中心和皇家墨尔本医院的临床试验负责人。Aaron曾担任多项姑息治疗临床试验的首席研究员。他正在完成由NHMRC研究生奖学金支持的博士学位,重点是利用药物基因组学研究生物标志物,以最佳选择阿片类药物来控制疼痛。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
175
审稿时长
6-12 weeks
期刊介绍: Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信